Matters
- Obtained dismissal of federal qui tam False Claims Act lawsuit alleging violation of Medicare Advantage marketing regulations, with damages alleged in the hundreds of millions of dollars.
- Briefed and argued appeal of dismissal of federal qui tam False Claims Act Lawsuit alleging violation of Medicare Advantage marketing regulations at the Eighth Circuit, secured victory on appeal in United States ex rel. Holt v. Medicare Medicaid Advisors, Inc., 115 F4th 908 (8th Cir. 2024).
- Led internal investigation concerning alleged fraud and conflicts of interest for multimillion-dollar federal healthcare contractor; led self-disclosure and negotiated favorable settlement with federal authorities.
- Led hospital-wide internal investigation concerning alleged HIPAA violations after widely publicized breach incident and subsequent litigation, advised board of directors on policy changes based upon investigation results.
- Obtained dismissal of federal qui tam False Claims Act lawsuit alleging false claims related to anesthesiology services.
- Secured DOJ declination of federal qui tam False Claims Act lawsuit alleging upcoding of gynecological surgical procedures, valued in the tens of millions of dollars.
- Secured DOJ declination of federal qui tam False Claims Act lawsuit alleging medically unnecessary spinal surgical procedures, valued in the tens of millions of dollars.
- Secured DOJ declination of federal qui tam False Claims Act lawsuit alleging violation of Medicare Advantage regulations, valued in the tens of millions of dollars.
- Secured declination and closure of investigation by DOJ of a nationally prosecuted DOJ case relating to allegations of violations of the Controlled Substances Act requirements for reporting of theft and loss of controlled substances.
- Representing major hospital system against federal government investigation of False Claims Act allegations.
- Defended Fortune 500 nationwide pharmacy against DOJ investigations of practices relating to the handling and dispensing of opioid medications.
- Successfully defended biotech executive regarding allegations of pharmaceutical research misconduct, including issues related to academic misconduct and federal funding.
- Negotiated favorable settlement after succeeding in dispositive motion hearing on behalf of former CEO in shareholder dispute arbitration.
- Obtained writ of attachment against pharmaceutical company via arbitration for payment due to a clinical trial research administration firm.*
*Denotes work at prior firm.
